このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Inventiva マネジメント

マネジメント基準チェック /24

Inventiva'sの CEO はFrederic Crenで、 Jan2011年に任命され、の在任期間は 13.42年です。の年間総報酬は€ 1.00Mで、 30.4%給与と69.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の10.72%を直接所有しており、その価値は€ 15.55M 。経営陣と取締役会の平均在任期間はそれぞれ7.8年と7.3年です。

主要情報

Frederic Cren

最高経営責任者

€1.0m

報酬総額

CEO給与比率	30.4%
CEO在任期間	13.4yrs
CEOの所有権	10.7%
経営陣の平均在職期間	7.8yrs
取締役会の平均在任期間	7.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Inventiva の収益と比較して、Frederic Cren の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	€1m	€305k	-€110m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€80m
Mar 31 2023	n/a	n/a	-€67m
Dec 31 2022	€878k	€300k	-€54m
Sep 30 2022	n/a	n/a	-€55m
Jun 30 2022	n/a	n/a	-€56m
Mar 31 2022	n/a	n/a	-€56m
Dec 31 2021	€929k	€299k	-€50m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€41m
Mar 31 2021	n/a	n/a	-€36m
Dec 31 2020	€388k	€267k	-€34m
Sep 30 2020	n/a	n/a	-€29m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€374k	€243k	-€30m
Sep 30 2019	n/a	n/a	-€34m
Jun 30 2019	n/a	n/a	-€37m
Mar 31 2019	n/a	n/a	-€35m
Dec 31 2018	€376k	€243k	-€33m
Sep 30 2018	n/a	n/a	-€29m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€22m
Dec 31 2017	€372k	€243k	-€19m

報酬と市場: Fredericの総報酬 ($USD 1.07M ) は、 German市場 ($USD 736.38K ) の同規模の企業の平均を上回っています。

報酬と収益: Fredericの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Frederic Cren (58 yo)

13.4yrs

在職期間

€1,003,699

報酬

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Frederic Cren	Co-Founder	13.4yrs	€1.00m	10.72% € 15.4m
Pierre Broqua	Co-Founder	13.4yrs	€938.43k	7.41% € 10.7m
Jean Volatier	Deputy GM & CFO	11.8yrs	データなし	0.29% € 412.0k
Alice Roudot-Ketelers	Chief Operating Officer	1.3yrs	データなし	0.029% € 41.2k
Eric Duranson	General Counsel	2.9yrs	データなし	0.029% € 41.2k
Nathalie Harroy	Head of Human Resources	12.4yrs	データなし	0.13% € 180.7k
Michael Cooreman	Chief Medical Officer	3.7yrs	データなし	0.029% € 41.2k
Pascaline Clerc	Executive Vice President of Strategy & Corporate Affairs	less than a year	データなし	0.014% € 20.6k

7.8yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: 6IVの経営陣は経験豊富で経験豊富です（平均在職期間は7.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Frederic Cren	Co-Founder	8.1yrs	€1.00m	10.72% € 15.4m
Pierre Broqua	Co-Founder	8.1yrs	€938.43k	7.41% € 10.7m
Chris Buyse	Independent Director	7.3yrs	€61.20k	0% € 0
Annick Schwebig	Independent Director	7.3yrs	€61.20k	0.0059% € 8.5k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	データなし
Xiaoqin Lu	Independent Director	6.1yrs	€43.20k	データなし
Heinz Maeusli	Independent Director	5.1yrs	€49.20k	データなし
Sven Francque	Member of Scientific Advisory Board	no data	データなし	データなし
Manal Abdelmalek	Member of Scientific Advisory Board	no data	データなし	データなし
Kenneth Cusi	Member of Scientific Advisory Board	no data	データなし	データなし
Glen Clack	Member of Scientific Advisory Board	no data	データなし	データなし
Gérard Zalcman	Scientific Advisory Board Member	no data	データなし	データなし

7.3yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: 6IVの取締役会は経験豊富であると考えられます ( 7.3年の平均在任期間)。

Inventiva マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Insufficient new directors

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Recent updates

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Full year 2023 earnings released: €2.44 loss per share (vs €1.31 loss in FY 2022)

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

First half 2023 earnings released: €1.32 loss per share (vs €0.72 loss in 1H 2022)

New major risk - Negative shareholders equity

New major risk - Financial position

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Full year 2022 earnings released: €1.31 loss per share (vs €1.27 loss in FY 2021)

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

First half 2022 earnings released: €0.72 loss per share (vs €0.60 loss in 1H 2021)

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Forecast to breakeven in 2024

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.29 loss in 2Q 2020)

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

First quarter 2021 earnings released: €0.23 loss per share (vs €0.23 loss in 1Q 2020)

Full year 2020 earnings released: €0.99 loss per share (vs €1.29 loss in FY 2019)

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

New 90-day high: €12.92

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

New 90-day high: €11.34

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

First half earnings released

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24